Get started
Author

Berkay Şímșek

Observed names: BERKAY ŞİMŞEK, Berkay Simsek, Berkay Şimşek, Şimşek, Berkay
ORCID: 0000-0002-3631-0903
Observed ORCID: 0000-0002-3631-0903
OpenAlex ID: A5062418237
Sinonasal SMARCB1 (INI1) Deficient Carcinoma with Yolk Sac Tumor Differentiation: A Case Report and Treatment Options
2021 · Burak Hazir, Berkay Şímșek, et al. · Head and Neck Pathology · 23
Risk of Malignancy Using the Diagnostic Categories Proposed by the World Health Organization International System for Reporting Pancreaticobiliary Cytopathology
2022 · Pınar Uyar Gocun, Berkay Simsek, et al. · Acta Cytologica · 15
PDF
Same-Slide Spatial Multi-Omics Integration Reveals Tumor Virus-Linked Spatial Reorganization of the Tumor Microenvironment
2024 · Yao Yu Yeo, Yuzhou Chang, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 12
Tertiary lymphoid structures harbour stem-like tumour-specific T cells
2026 · Alexander B. Afeyan, Adi Nagler, et al. · Nature · 5
Same-Slide Spatial Multiomics Integration with IN-DEPTH Reveals Tumor Virus–Linked Spatial Reorganization of the Tumor Microenvironment
2026 · Stephanie Pei Tung Yiu, Yuzhou Chang, et al. · Cancer Discovery · 5
PDF
Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
2026 · Nourhan El Ahmar, Morgan A. Paul, et al. · Clinical Cancer Research · 2
PDF
831 AXL Receptor Tyrosine Kinase Expression in Metastatic Renal Cell Carcinoma: Insights from the METEOR trial
2025 · Yasmin Laimon, Morgan Paul, et al. · Laboratory Investigation · 2
Transcription Factor Subtype Governs Response and Resistance to DLL3-Directed T-Cell Engagement in Small Cell Lung Cancer
2026 · Damien Vasseur, Shin Saito, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 1
Abstract A003: Baseline levels of HIF2 target proteins and response to the HIF2α inhibitor NKT2152 in patients with metastatic clear cell renal cell carcinoma
2025 · Gabriel Roberti. de Oliveira, Berkay Simsek, et al. · Molecular Cancer Therapeutics · 1
Germline determinants of pneumonitis in patients with cancer treated with antibody drug conjugates.
2025 · Emre Yekeduz, Eddy Saad, et al. · Journal of Clinical Oncology · 1
PDF
Benign Multicystic Peritoneal Mesothelioma: Two Rare Cases and Review of the Literature
2023 · Mustafa Mehmet Incesu, Murat Ucar, et al. · Current Medical Imaging Formerly Current Medical Imaging Reviews · 1
Painful Testicular Metastasis of Prostate Cancer; A Case Report
2023 · Hikmat Jabrayilov, Jeyhun Hasanov, et al. · Bulletin of Urooncology · 1
PDF
Supplementary Table S9 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
2026 · Nourhan El Ahmar, Morgan A. Paul, et al.
Supplementary Table S3 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
2026 · Nourhan El Ahmar, Morgan A. Paul, et al.
Supplementary Table S6 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
2026 · Nourhan El Ahmar, Morgan A. Paul, et al.
Supplementary Table S4 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
2026 · Nourhan El Ahmar, Morgan A. Paul, et al.
Supplementary Table S7 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
2026 · Nourhan El Ahmar, Morgan A. Paul, et al.
Supplementary Table S11 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
2026 · Nourhan El Ahmar, Morgan A. Paul, et al.
Supplementary Table S10 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
2026 · Nourhan El Ahmar, Morgan A. Paul, et al.
Supplementary Figure S1 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
2026 · Nourhan El Ahmar, Morgan A. Paul, et al.
Data from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
2026 · Nourhan El Ahmar, Morgan A. Paul, et al.
Supplementary Table S8 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
2026 · Nourhan El Ahmar, Morgan A. Paul, et al.
Supplementary Table S5 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
2026 · Nourhan El Ahmar, Morgan A. Paul, et al.
Supplementary Figure S5 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
2026 · Nourhan El Ahmar, Morgan A. Paul, et al.
Supplementary Figure S2 from Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti–PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial
2026 · Nourhan El Ahmar, Morgan A. Paul, et al.
Works count: 70
Citation count: 69
H-index: 5
I10-index: 3
Year
Topic
Type